Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25…
Growing Federal Investment in Health IT, Government-Backed Incentive Programs, and Accelerating AI-Assisted Clinical Documentation Tools Fuel Market Expansion. Austin, United…